Does Sharp Health Plan Cover Eliquis?

How Sharp Health Plan Handles Eliquis on Its Formulary

Sharp Health Plan, a San Diego-based HMO, includes Eliquis on its prescription drug formulary for most commercial and Medicare Advantage plans. The specific tier placement determines what you pay out of pocket each month. Sharp publishes its formulary annually and updates it quarterly, so checking the most recent version matters.

Tier Placement and What It Means for Your Wallet

On most Sharp commercial HMO plans, Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 drugs typically carry a copay between $40 and $65 per 30-day supply. Tier 4 placement pushes that range to $70 to $95. The distinction depends on which specific Sharp plan your employer selected or which individual plan you enrolled in through Covered California.

Sharp Medicare Advantage plans (Sharp Direct Advantage and Sharp Performance Plus) follow the CMS Part D formulary structure. On these plans, Eliquis usually falls into Tier 3 with coinsurance of 25% to 33% after the deductible, though the Medicare Part D Coverage Gap Discount Program reduces manufacturer costs during the "donut hole" phase.

How to Verify Your Specific Plan

Sharp's online formulary lookup tool at sharphealthplan.com lets you search for Eliquis by name. You can also call Sharp Member Services at 1-800-359-2002 with your member ID to get your exact copay, tier, and any utilization management restrictions. Keep your plan's Evidence of Coverage (EOC) document handy. That document is the binding contract.

Understanding Eliquis: Why Doctors Prescribe It

Eliquis (apixaban) is a Factor Xa inhibitor that blocks a key protein in the clotting cascade. The FDA approved it in 2012 for reducing stroke risk in patients with non-valvular atrial fibrillation. It now carries five FDA-approved indications.

Clinical Evidence Behind Eliquis

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with atrial fibrillation. Apixaban reduced the rate of stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority, P=0.01 for superiority) while also lowering major bleeding by 31% [1]. That dual benefit, less clotting and less bleeding, is rare among anticoagulants.

For DVT and PE treatment, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to standard enoxaparin/warfarin therapy for recurrent VTE, with significantly less major bleeding (0.6% vs. 1.8%, relative risk reduction of 69%) [2].

The American College of Cardiology and American Heart Association 2019 AF Guidelines recommend DOACs, including apixaban, over warfarin for most patients with non-valvular atrial fibrillation who are eligible for oral anticoagulation (Class I recommendation) [3].

Who Typically Gets Prescribed Eliquis

Your cardiologist or primary care physician may prescribe Eliquis if you have atrial fibrillation with a CHA₂DS₂-VASc score of 2 or higher (1 or higher in men), a recent deep vein thrombosis or pulmonary embolism, or you are undergoing hip or knee replacement surgery. Patients with mechanical heart valves or moderate-to-severe mitral stenosis should not take Eliquis. Those conditions require warfarin.

Prior Authorization and Step Therapy at Sharp

Sharp Health Plan does not require prior authorization for Eliquis on every plan. But some plans use step therapy, which means your doctor must document that you tried warfarin first (or that warfarin is clinically inappropriate) before Sharp approves Eliquis coverage.

When Step Therapy Applies

Step therapy is more common on Sharp's lower-premium commercial plans and some Covered California Silver-tier HMOs. If your plan enforces step therapy, your prescriber needs to submit documentation showing one of these: a history of warfarin use with poor INR control, a documented warfarin allergy or adverse reaction, a drug-drug interaction making warfarin unsafe, or a clinical rationale such as high fall risk or inability to attend regular INR monitoring.

How to Request an Exception

If Sharp denies coverage or requires step therapy that your doctor considers medically inappropriate, you can file a formulary exception request. Sharp must respond within 72 hours for standard requests and 24 hours for expedited (urgent) requests under California Department of Managed Health Care regulations. Your prescriber submits a letter of medical necessity explaining why Eliquis is required instead of the step therapy alternative.

The Sharp Exception Process, Step by Step

1. Your prescriber calls Sharp's Pharmacy Department at 1-800-359-2002.
2. Sharp faxes or emails the exception request form.
3. Your prescriber completes the form, attaching clinical notes (CHA₂DS₂-VASc score, bleeding risk via HAS-BLED, prior warfarin history).
4. Sharp's pharmacy team reviews and issues a decision within 72 hours (standard) or 24 hours (expedient).
5. If denied, you or your prescriber can appeal through Sharp's internal appeals process or escalate to the California DMHC Independent Medical Review.

What Eliquis Costs on Sharp Health Plan

The retail price for Eliquis without insurance averages $580 to $620 for a 30-day supply of 5 mg twice daily. Sharp coverage reduces this substantially, but your actual out-of-pocket cost depends on your plan tier, deductible status, and whether you have hit your annual out-of-pocket maximum.

Commercial Plan Cost Estimates

On a Sharp Tier 3 plan: expect $40 to $65 per month after any applicable deductible. On a Sharp Tier 4 plan: expect $70 to $95 per month. If your plan has a pharmacy deductible (common on HSA-qualified plans), you pay the full negotiated rate until meeting that deductible, which can be $500 to $1,500 for individual coverage.

Medicare Advantage Cost Estimates

Sharp Direct Advantage (HMO) and Sharp Performance Plus (HMO-POS) plans follow Part D cost-sharing. During the Initial Coverage Phase, you typically pay 25% to 33% coinsurance on Tier 3 drugs. Once you enter the Coverage Gap, manufacturer discounts through the Inflation Reduction Act provisions cap your out-of-pocket for brand drugs.

Starting in 2025, the Part D $2,000 annual out-of-pocket cap means no Sharp Medicare Advantage member pays more than $2,000 total for all Part D drugs in a calendar year [4]. For someone taking only Eliquis, this cap may be reached in 6 to 10 months depending on coinsurance rates.

Reducing Your Eliquis Costs on Sharp

The BMS/Pfizer Eliquis copay card covers commercially insured patients and can reduce your copay to as low as $10 per month, up to a maximum annual benefit. This card does not work with Medicare, Medicaid, or other government-funded plans. If you are on Sharp Medicare Advantage, the Extra Help/Low Income Subsidy program through Social Security can reduce your copays to $0 to $11 per prescription.

Eliquis vs. Other Anticoagulants Covered by Sharp

Sharp's formulary includes several anticoagulant options. Your out-of-pocket cost and clinical profile help determine which one makes sense.

Warfarin (Generic)

Warfarin sits at Tier 1 (generic) on virtually all Sharp plans, costing $0 to $15 per month. It requires regular INR blood monitoring (typically every 2 to 4 weeks), has numerous food and drug interactions, and carries a higher intracranial hemorrhage risk than Eliquis. The ARISTOTLE trial demonstrated apixaban's superiority to warfarin for both efficacy and safety in atrial fibrillation [1]. Dr. Christopher Granger, lead ARISTOTLE investigator at Duke University, stated: "Apixaban was superior to warfarin in preventing stroke, caused less bleeding, and resulted in lower mortality" [5].

Xarelto (Rivarobaxan)

Xarelto is typically Tier 3 on Sharp formularies with a similar copay to Eliquis. It is dosed once daily (a convenience advantage) but showed higher GI bleeding rates than apixaban in the observational ARISTOPHANES study (N=285,292), which found apixaban associated with a 33% lower risk of major GI bleeding compared to rivaroxaban [6].

Savaysa (Edoxaban)

Savaysa may appear at Tier 3 or Tier 4 on Sharp plans. The ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban noninferior to warfarin for stroke prevention, with lower major bleeding rates [7]. It is less commonly prescribed than Eliquis or Xarelto in clinical practice.

How to Fill Your Eliquis Prescription Through Sharp

Sharp Health Plan partners with specific pharmacy networks. Where you fill your prescription affects your copay.

Preferred Pharmacy Network

Sharp's preferred pharmacy partners in San Diego County include Sharp Rees-Stealy pharmacies, CVS Pharmacy, and select independent pharmacies. Filling at a preferred pharmacy gives you the lowest copay tier. Using a non-preferred pharmacy may increase your cost by $10 to $25 per fill.

Mail-Order Option

Sharp offers mail-order pharmacy through its contracted vendor for 90-day supplies. A 90-day Eliquis fill through mail order typically costs 2 to 2.5 times the 30-day copay (not 3 times), saving you one month's copay over three months. This also reduces the risk of gaps in anticoagulation therapy from missed refills.

Specialty Pharmacy Considerations

Eliquis is not classified as a specialty drug, so it does not require specialty pharmacy dispensing. You can fill it at any in-network retail or mail-order pharmacy. This is a meaningful distinction because specialty pharmacy copays on Sharp plans can be 30% to 40% coinsurance, significantly more than the flat copay for non-specialty brands.

Switching to Sharp Health Plan With an Existing Eliquis Prescription

If you are moving to a Sharp plan during Open Enrollment or a Special Enrollment Period and already take Eliquis, plan your transition carefully.

Transition Supply Rules

California law (Health & Safety Code §1367.22) requires health plans to provide a temporary supply of ongoing medications during plan transitions, typically 30 to 180 days depending on the situation. Sharp must cover at least a 30-day supply of Eliquis while your new prescriber reviews your treatment plan, even if the drug requires prior authorization under your new Sharp plan.

Coordinating With Your New Prescriber

Sharp is a staff-model and network-model HMO, meaning you need a Sharp-affiliated primary care provider. During your first visit, bring your current medication list, your most recent INR or anti-Xa level (if available), and documentation of your diagnosis. Your new Sharp prescriber can then write the Eliquis prescription under your Sharp coverage. If step therapy applies, the medical records from your prior plan documenting your anticoagulation history serve as the clinical justification to bypass it.

What Happens If Sharp Denies Eliquis Coverage

A denial is not the end. Sharp plan members in California have strong appeal rights.

Internal Appeal

You or your prescriber can file an internal appeal within 180 days of the denial. Sharp must issue a decision within 30 days for standard appeals and 72 hours for urgent appeals. Include all supporting clinical documentation: your CHA₂DS₂-VASc score, HAS-BLED score, any prior anticoagulant trials, and relevant guidelines from the ACC/AHA supporting DOAC use [3].

External Review Through California DMHC

If Sharp upholds its denial, you can request an Independent Medical Review through the California Department of Managed Health Care (DMHC) at 1-888-466-2219. The DMHC assigns an independent physician reviewer who is not affiliated with Sharp. California DMHC data shows that approximately 60% of prescription drug IMRs are decided in the patient's favor.

The Endocrine Society's 2023 clinical practice guidelines note that anticoagulant selection should be individualized based on renal function, bleeding risk, and patient preference, a principle that supports exception requests when a specific DOAC is clinically preferred over alternatives [8].

Monitoring While on Eliquis Through Sharp

Unlike warfarin, Eliquis does not require routine INR testing. This reduces the monitoring burden on both you and your Sharp-affiliated care team.

Recommended Lab Schedule

The American Society of Hematology recommends baseline and periodic monitoring including a complete blood count (CBC) every 6 to 12 months, renal function (serum creatinine and eGFR) at least annually, and hepatic function at baseline [9]. Your Sharp primary care provider typically orders these during routine annual lab work, so no extra visits are needed.

Dose Adjustments Based on Patient Factors

Standard Eliquis dosing is 5 mg twice daily for atrial fibrillation. The dose is reduced to 2.5 mg twice daily if a patient meets two or more of these criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. For DVT/PE treatment, the dose is 10 mg twice daily for 7 days, followed by 5 mg twice daily. Your Sharp prescriber adjusts dosing based on your specific clinical profile. The FDA prescribing information details all dose-adjustment criteria [10].

Looking Ahead: Generic Apixaban and Sharp Formulary Changes

No FDA-approved generic version of apixaban exists as of May 2026. Bristol-Myers Squibb's key U.S. Patents on Eliquis extend through 2026 to 2031, depending on the specific patent. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA, and patent litigation settlements suggest generic entry could occur as early as late 2026 or 2027.

When a generic becomes available, Sharp Health Plan will likely move it to Tier 1 or Tier 2, dropping the copay to $0 to $20 per month. At that point, Sharp may also impose step therapy requiring the generic before covering brand Eliquis, similar to how statin formularies evolved after generic atorvastatin became available.

For now, your best cost-reduction strategy is combining Sharp coverage with the BMS/Pfizer copay card (commercial plans) or the Part D $2,000 cap (Medicare Advantage). Confirm your copay by calling Sharp Member Services at 1-800-359-2002 with your member ID before your next refill.